Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor

NCT03459469 is registered in ClinicalTrials.gov with Iterion Therapeutics as lead sponsor.

NCT NCT03459469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03459469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Lead sponsor
Iterion Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
July 15, 2018
Completion date
May 1, 2022
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

desmoid tumor